Skip to content

Helius Medical Receives FDA Breakthrough Device Designation For PoNS – Shares Rally

Helius Medical Technologies (NASDAQ: HSDT) announced on Tuesday that it has received Breakthrough Designation from the U.S. Food and Drug Administration (FDA) for its PoNS device.

The designation is for use as a temporary treatment of dynamic gait and balance deficits due to symptoms from a stroke. It is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over.

“We are very pleased to announce the receipt of Breakthrough Designation for our PoNS device to treat stroke-induced gait and balance deficits,” said Helius CEO Dane Andreeff.

“Strokes are a large and growing cause of long-term disability in the United States. An estimated 7 million Americans are living with stroke-related complications, and more than 80% of stroke survivors are estimated to develop gait impairment,” added Andreeff.

Helius Medical’s share price has climbed 17.6% to $16.90 following the announcement.

Should You Invest in Helius Medical Shares?

One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It’s a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now

Sam Boughedda
Sam Boughedda
Team Member

Sam is a trader and lead stock market writer at AskTraders. After starting his career in the forex market, Sam now focuses on stocks, specifically consumer staples. 

Stay ahead of the markets

Sign up to our free Morning Markets email, every weekday before the open.